Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by levelWhat for?
by area of lawAll areas of law
- Bribery and corruption €5.02bn 95 % · 7 cases
- Competition law €206.3m 4 % · 2 cases
- Sanctions and export control €22.1m 0 % · 2 cases
- Environment and sustainability €20.7m 0 % · 2 cases
- Whistleblower protection €210,202 0 % · 1 case
- Health and safety and employment law €157,452 0 % · 1 case
- Supply chain and human rights – 0 % · 1 case
Who?
by company- Purdue Pharma L.P. €4.75bn 90 % · 1 case
- Anonymised companies €225.3m 4 % · 3 cases
- Gilead Sciences, Inc. €177.8m 3 % · 1 case
- Pfizer Inc. (für die Tochter Biohaven Pharmaceutical Holding Company Ltd.) €57.1m 1 % · 1 case
- Dompé U.S. Inc. €27.5m 1 % · 1 case
- The Chemours Company; The Chemours Company FC, LLC €19.8m 0 % · 1 case
- Takeda Pharmaceuticals U.S.A., Inc. €11.7m 0 % · 1 case
- EyePoint Pharmaceuticals, Inc. €4.08m 0 % · 1 case
- Unicat Catalyst Technologies, LLC €3.35m 0 % · 1 case
- Denka Performance Elastomer, LLC €874,915 0 % · 1 case
- 4 more€157,452
When?
per year, by date of decision| Period | Cases | Total |
|---|---|---|
| 2023 | 2 | €206.5m |
| 2024 | 1 | €18.8m |
| 2025 | 4 | €238.4m |
| 2026 | 9 | €4.81bn |
16 cases
10 Sep 2026 Dompé U.S. Inc.Dompé U.S.: 32 million USD – Medicare patients’ co-payments covered via foundations €27.5m
From 2018 to 2021, the pharmaceutical manufacturer allegedly used two patient assistance foundations to fund Medicare beneficiaries’ co-payments for its drug Oxervate in order to promote its sales. Following a self-disclosure, Dompé paid 32 million USD.
Benefits flowing to customers via foundations or other third parties remain benefits provided by the company – donations to patient assistance programmes require strict independence.
Benefits to patients and customers via third parties
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- Self-disclosure.
Original amount 32,000,000 USD, converted at the ECB reference rate of 10 Sep 2026.
- HHS-OIG Enforcement Actions: Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks (10.09.2026) Enforcement database of an authority
- U.S. Department of Justice: Dompé U.S. Agrees to Pay $32M to Resolve False Claims Act Liability Relating to Self-Disclosure of Patient Kickbacks (10.09.2026) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
14 Aug 2026 Henkel AG & Co. KGaAHenkel/Liquid Nails: court blocks takeover of Loctite’s main competitor Order
Henkel wanted to buy the construction adhesive brand Liquid Nails for 725 million USD from the financial investor American Industrial Partners, thereby taking over the main competitor of its Loctite brand. After a seven-day trial, the federal court, on application by the Federal Trade Commission (FTC), issued a permanent injunction against the acquisition.
Acquiring the closest competitor carries a high risk of prohibition, even at a moderate deal volume.
- Authority / court
- U.S. District Court for the Southern District of New York (auf Antrag der FTC)
- Area of law
- Competition law · Merger control
- Legal basis
- Section 7 Clayton Act; Section 13(b) FTC Act (Permanent Injunction)
- Action
- Order
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Published
- 17 Aug 2026
- Statement on FTC Win Blocking Loctite, Liquid Nails Construction Adhesive Merger (17.08.2026) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
10 Aug 2026 Veloxis Pharmaceuticals Inc.Veloxis: over 46 million USD – luxury trips, dinners and gifts for transplant teams Other
From 2016 to 2023, Veloxis provided transplant professionals with expensive meals and alcohol, trips and stays at luxury resorts, gifts and consultancy fees without consideration, and paid specialty pharmacies concealed remuneration in order to promote prescriptions and purchases of the immunosuppressant Envarsus XR. The company entered into a Deferred Prosecution Agreement with a criminal payment of more than 10 million USD, is paying 34.45 million USD under civil law (21,211,251 USD to the federal government, 13,238,749 USD to states) and a penalty of 1.55 million USD under the Sunshine Act (Open Payments) – the highest to date – totalling over 46 million USD.
Invitations and gifts to decision-makers must not only be limited but also fully reported to transparency registers.
Gifts, travel and hospitality for healthcare professionals; transparency reporting
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute; False Claims Act; Physician Payments Sunshine Act (Open Payments)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- DOJ: Veloxis Pharmaceuticals Agrees to Pay Over $46M to Resolve Criminal and Civil Liability for Kickback Schemes (10.08.2026) Press release of an authority
- HHS-OIG Enforcement Actions: Veloxis Pharmaceuticals Agrees to Pay Over $46M … (10.08.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
3 Aug 2026 Guangxi Kelun Pharmaceutical Co., Ltd.UFLPA list: antibiotics manufacturer Guangxi Kelun Pharmaceutical added Order
The U.S. Forced Labor Enforcement Task Force (FLETF) listed the manufacturer of cephalosporin antibiotics because it sources antibiotic intermediates from Yili Chuanning Biotechnology in Xinjiang. The company's goods are therefore presumed to have been produced with forced labour on import into the US unless the importer rebuts this.
Pharmaceutical companies must be able to trace their supply chains back to active ingredient intermediates.
- Authority / court
- U.S. Department of Homeland Security (Forced Labor Enforcement Task Force)
- Area of law
- Supply chain and human rights · Forced and child labour
- Legal basis
- Uyghur Forced Labor Prevention Act, Section 2(d)(2)(B)(v)
- Action
- Order
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Published
- 3 Aug 2026
- Federal Register: Notice Regarding the Uyghur Forced Labor Prevention Act Entity List (03.08.2026) Official register or notice
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
20 Jul 2026 EyePoint Pharmaceuticals, Inc.EyePoint: 4.66 million USD – kickbacks to surgery centres for purchasing an eye medicine €4.08m
Between January 2019 and March 2023, the pharmaceutical manufacturer allegedly paid kickbacks to ambulatory surgery centres to induce them to purchase and use the injectable drug DEXYCU for cataract surgery. To resolve the False Claims Act allegations, EyePoint paid 4,657,463.18 USD and entered into a Corporate Integrity Agreement with HHS-OIG.
Discounts, payments or services to institutions that make purchasing decisions require a documented consideration at market value.
Granting benefits to customers and purchasing decision-makers
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
Original amount 4,657,463.18 USD, converted at the ECB reference rate of 20 Jul 2026.
- HHS-OIG Enforcement Actions: EyePoint Pharmaceuticals to Pay $4.6 Million to Resolve False Claims Act Allegations (20.07.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
24 Jun 2026 The Chemours Company; The Chemours Company FC, LLCChemours: USD 22.5m civil penalty in PFAS settlement with EPA and West Virginia €19.8m
The EPA, the US Department of Justice and West Virginia's environmental agency reached a settlement (consent decree) with Chemours over PFAS discharges into the Cape Fear, Delaware and Ohio rivers, some made without and some in breach of discharge permits, together with TSCA and RCRA violations at four plants. Chemours will pay a civil penalty of 22,500,000 USD in three annual instalments of 7,500,000 USD and carry out remedial measures, including drinking water supply, PFAS controls and a USD 90m mitigation programme, which the EPA puts at over USD 450m in total. The settlement was lodged with the court on 24 June 2026 and is subject to public comment and court approval. The authority allegedly made the findings set out here; this account is not based on a final judgment. The decision is not final.
PFAS manufacturers must continuously check every discharge against their permits – unregulated flows lead to penalties and costly obligations towards local residents.
Discharge permits and PFAS emissions
- Authority / court
- U.S. Environmental Protection Agency (EPA) / U.S. Department of Justice mit West Virginia Department of Environmental Protection (U.S. District Court, Southern District of West Virginia)
- Area of law
- Environment and sustainability · Emissions and permits
- Legal basis
- Clean Water Act (NPDES); Resource Conservation and Recovery Act; Toxic Substances Control Act; West Virginia Water Pollution Control Act
- Action
- Fine
- Status of proceedings
- not yet final
- Sector
- Chemicals and pharmaceuticals
- Mitigating circumstances
- The civil penalty was set on the basis of the company's ability to pay.
- Published
- 24 Jun 2026
Original amount 22,500,000 USD, converted at the ECB reference rate of 24 Jun 2026.
- EPA: Chemours Settlement Summary - June 2026 Press release of an authority
- EPA News Release, 24.06.2026: EPA Obtains Over $450 Million In Penalties and Relief in Agreement with Chemours Press release of an authority
- Proposed Consent Decree, United States and West Virginia v. The Chemours Company, Civil Action 2:26-cv-00418 (S.D. W. Va.), lodged 24.06.2026 Decision of an authority
Checked against the official source on 3 Oct 2026 · Direct link
Report an error
23 Jun 2026 Denka Performance Elastomer, LLCDenka Performance Elastomer: USD 996,703 over hazardous waste at neoprene plant €874,915
The EPA (Region 6) issued a Consent Agreement and Final Order against Denka Performance Elastomer over RCRA violations at its neoprene plant in LaPlace (Louisiana): missing waste determinations, breaches of land disposal restrictions and treatment and storage of hazardous waste without a permit. Denka will pay 996,703.35 USD and must clean out a brine pit and its ancillary equipment; if the currently idle plant resumes operations, further requirements apply, including on waste inventory, containers, training and protective equipment. The authority allegedly made the findings set out here; this account is not based on a final judgment.
Every waste stream needs a documented determination of whether it is hazardous – without it there is no basis for lawful storage, treatment and disposal.
Classification and storage of hazardous waste
Missing or inadequate training played a role in the decision.
- Authority / court
- U.S. Environmental Protection Agency (EPA), Region 6
- Area of law
- Environment and sustainability · Waste and hazardous substances
- Legal basis
- Resource Conservation and Recovery Act (RCRA), Docket RCRA-06-2025-0910
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Repeat case
- yes
- Published
- 2 Jul 2026
Original amount 996,703.35 USD, converted at the ECB reference rate of 23 Jun 2026.
- EPA: Denka Performance Elastomer RCRA Settlement Summary Press release of an authority
- EPA Region 6: Consent Agreement and Final Order, Denka Performance Elastomer LLC, Docket No. RCRA-06-2025-0910 Decision of an authority
- EPA News Release, 02.07.2026: EPA Final Settlement with Denka Performance Elastomer Press release of an authority
Checked against the official source on 3 Oct 2026 · Direct link
Report an error
14 May 2026 Takeda Pharmaceuticals U.S.A., Inc.Takeda: 13.7 million USD – speaker fees and luxury meals for prescribing physicians €11.7m
From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.
Speaker programmes need a demonstrable educational purpose – repeated attendance and expensive hospitality turn them into inducements.
Invitations, hospitality and fees for healthcare professionals
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.
- DOJ: Takeda Agrees to Pay $13.6M to Resolve False Claims Allegations Relating to Improper Payments (14.05.2026) Press release of an authority
- HHS-OIG Enforcement Actions: Takeda Agrees to Pay $13.6M … Improper Payments to Physicians (14.05.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
28 Apr 2026 Purdue Pharma L.P.Purdue Pharma: 5.544 billion USD penalty – including kickbacks via the speaker programme €4.75bn
Following its 2020 guilty plea, the opioid manufacturer was sentenced in Newark to a criminal fine of 3.544 billion USD (asserted in the insolvency proceedings) and forfeiture of 2 billion USD; up to 1.775 billion USD can be credited against the forfeiture if Purdue emerges from insolvency as a public benefit company. Purdue had deceived the DEA and paid kickbacks to prescribers via its speaker programme and to an electronic health records platform in order to increase opioid prescriptions.
Fee programmes for customers who drive revenue can become part of a criminal overall scheme – with consequences that threaten the company’s existence.
Speaker fees and benefits for prescribing physicians
- Authority / court
- U.S. District Court, District of New Jersey (Anklage: U.S. Department of Justice)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Verschwörung zum Betrug der USA und zur Verletzung des Food, Drug, and Cosmetic Act; zwei Fälle Verschwörung zur Verletzung des Anti-Kickback Statute (Schuldbekenntnis vom 24.11.2020)
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Culpability
- intentional
Original amount 5,544,000,000 USD, converted at the ECB reference rate of 28 Apr 2026.
- HHS-OIG Enforcement Actions: Opioid Manufacturer Purdue Pharma Sentenced for Fraud and Kickback Conspiracies (28.04.2026) Enforcement database of an authority
- U.S. Department of Justice: Opioid Manufacturer Purdue Pharma Sentenced for Fraud and Kickback Conspiracies (28.04.2026) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
16 Jun 2025 Unicat Catalyst Technologies, LLCCatalyst manufacturer Unicat supplied Iran and blocked Venezuelan company €3.35m
In 2016–2021, the Texas supplier of catalysts for refineries and steelworks supplied products and advice to customers in Iran via employees and agents, and sold goods to a blocked Venezuelan company. The US Treasury's Office of Foreign Assets Control (OFAC) considered it an egregious but voluntarily self-disclosed case; there were parallel settlements with the DOJ and BIS, which were taken into account in determining the amount.
When senior management itself steers embargo business, only independent controls and whistleblower channels help – voluntary self-disclosure after discovery reduces the penalty but does not prevent it.
- Authority / court
- U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)
- Area of law
- Sanctions and export control · Breaches of sanctions and embargoes
- Legal basis
- Iranian Transactions and Sanctions Regulations; Venezuela Sanctions Regulations; IEEPA
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Culpability
- intentional
- Mitigating circumstances
- Voluntary self-disclosure, cooperation and remedial measures after discovery
- Liability of senior managers
- Measures against individuals are not reported here.
- Published
- 16 Jun 2025
Original amount 3,882,797 USD, converted at the ECB reference rate of 16 Jun 2025.
- OFAC Enforcement Release: Unicat Catalyst Technologies, LLC Settles with OFAC for $3,882,797 (16.06.2025) Decision of an authority
- OFAC – 2025 Enforcement Information Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 2 · Direct link
Report an error
28 Apr 2025 Gilead Sciences, Inc.Gilead: 202 million USD – speaker programmes with fees, luxury meals and travel €177.8m
Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.
Selecting speakers by prescription volume turns continuing education into bribery – selection criteria and hospitality limits must be documented.
Fees and hospitality at professional events
- Authority / court
- U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Published
- 29 Apr 2025
Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.
- HHS-OIG Enforcement Actions: U.S. Attorney Announces $202 Million Settlement With Gilead Sciences … Speaker Programs (29.04.2025) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
24 Jan 2025 Pfizer Inc. (für die Tochter Biohaven Pharmaceutical Holding Company Ltd.)Pfizer/Biohaven: USD 59.7m over speaker fees and lavish meals for doctors €57.1m
Pfizer pays USD 59,746,277 on behalf of its subsidiary Biohaven to resolve False Claims Act and Anti-Kickback Statute allegations relating to the period before the acquisition; about USD 50.2 million goes to the federal government and about USD 9.5 million to state Medicaid programmes. From March 2020 to September 2022 Biohaven allegedly gave selected doctors speaker fees and meals at expensive restaurants to encourage prescriptions of the migraine drug Nurtec ODT; some events were attended repeatedly by the same doctors or by spouses, relatives and practice colleagues with no educational need.
In acquisitions, the target's speaker programmes and payments to doctors belong in due diligence – the liability passes to the buyer.
Speaker programmes: selection of speakers, repeat attendance, hospitality
- Authority / court
- U.S. Department of Justice (Civil Division; USAO Western District of New York)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- False Claims Act; Anti-Kickback Statute
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Published
- 24 Jan 2025
Original amount 59,746,277 USD, converted at the ECB reference rate of 24 Jan 2025.
- Pfizer Agrees to Pay Nearly 60M to Resolve False Claims Allegations Relating to Improper Physician Payments by Subsidiary (DOJ, 24.01.2025) Press release of an authority
- Pfizer agrees to pay nearly $60 million to resolve false claims allegations (USAO W.D.N.Y., 24.01.2025) Press release of an authority
Checked against the official source on 3 Oct 2026 · Direct link
Report an error
14 Jan 2025 AFCO (Tochtergesellschaft der Zep Inc.)Zep subsidiary AFCO: $161,310 proposed after nitrogen dioxide release €157,452
In July 2024, nitrogen dioxide above the exposure limit was released during chemical processing at the plant of Zep subsidiary AFCO in Chambersburg (Pennsylvania); twelve employees were examined in hospital and two were admitted. The U.S. Occupational Safety and Health Administration (OSHA) criticised the lack of an emergency action plan, deficient respiratory protection and hazard communication programmes and a delayed evacuation, and proposed $161,310 (including one repeat violation).
In the event of a chemical release, a rehearsed emergency and evacuation plan determines how many employees come to harm.
Responding to gas releases and evacuation
- Authority / court
- U.S. Department of Labor – Occupational Safety and Health Administration (OSHA)
- Area of law
- Health and safety and employment law · Workplace safety and accidents
- Legal basis
- 29 CFR 1910.120, 1910.134, 1910.1200
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Repeat case
- yes
- Published
- 14 Jan 2025
Original amount 161,310 USD, converted at the ECB reference rate of 14 Jan 2025.
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
19 Apr 2024 a Thai plastics companyThai plastics company pays 20 million USD for concealed sales of Iranian polyethylene €18.8m
In 2017–2018, the Thai plastics company had US banks process 467 payments totalling 291 million USD for HDPE plastic produced in an Iranian joint venture with the Iranian state-owned petrochemical group. Shipping and documentation practices concealed the Iranian origin. The penalty was imposed by the US Treasury's Office of Foreign Assets Control (OFAC).
Invoicing in US dollars brings US sanctions law into the business – holdings in embargoed countries require strict separation of payment flows.
- Authority / court
- U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC)
- Area of law
- Sanctions and export control · Breaches of sanctions and embargoes
- Legal basis
- Iranian Transactions and Sanctions Regulations (31 C.F.R. part 560)
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Culpability
- intentional
- Published
- 19 Apr 2024
Original amount 20,000,000 USD, converted at the ECB reference rate of 19 Apr 2024.
- OFAC, Civil Penalties and Enforcement Information (Übersicht) (Entscheidung 2024) Decision of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 19 Apr 2026 · Direct link
Report an error
8 Sep 2023 a US cleantech companySEC: US cleantech firm pays 225,000 US dollars over award waivers €210,202
From February 2020 to March 2023, the unlisted cleantech company (around 236 employees) had 22 departing employees waive awards for reports to authorities. After contact by the U.S. Securities and Exchange Commission (SEC), the company amended the agreements and informed those affected; the penalty amounted to 225,000 US dollars.
Unlisted companies are also subject to the SEC's whistleblower protection rules.
Whistleblower protection in contract templates (HR/Legal)
- Authority / court
- U.S. Securities and Exchange Commission
- Area of law
- Whistleblower protection · Retaliation against whistleblowers
- Legal basis
- Securities Exchange Act of 1934, Rule 21F-17(a)
- Action
- Fine
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Employees
- 50 to 249
- Mitigating circumstances
- Revision of the separation agreements and information provided to the former employees affected
- Published
- 8 Sep 2023
Original amount 225,000 USD, converted at the ECB reference rate of 8 Sep 2023.
- SEC, Administrative Proceedings (Übersicht) (Entscheidung 2023) Decision of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 8 Sep 2025 · Direct link
Report an error
21 Aug 2023 a US generic drug manufacturerDOJ: generics manufacturer pays 225 million USD criminal penalty over generic drug price fixing €206.3m
In a Deferred Prosecution Agreement, the manufacturer admitted to three conspiracies involving price fixing, customer allocation and bid rigging for generic drugs (including pravastatin). The manufacturer is paying a criminal penalty of 225 million USD in instalments, donating medicines worth 50 million USD and must divest its pravastatin business under the supervision of a monitor.
In addition to penalties running into millions, antitrust violations can force companies to divest entire product lines.
Agreements among generic drug manufacturers on prices and customers
- Authority / court
- U.S. Department of Justice, Antitrust Division
- Area of law
- Competition law · Cartels and collusion
- Legal basis
- 15 U.S.C. § 1 (Sherman Act)
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
Original amount 225,000,000 USD, converted at the ECB reference rate of 21 Aug 2023.
- DOJ Antitrust Division, Case Filings (Übersicht) (Entscheidung 2023) Decision of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 21 Aug 2025 · Direct link